Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)

NCT05652686 is registered in ClinicalTrials.gov with Phanes Therapeutics as lead sponsor.

NCT NCT05652686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05652686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)
Lead sponsor
Phanes Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 5, 2023
Completion date
August 31, 2028
Enrollment
203 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

extrapulmonary neuroendocrine carcinoma (ep-nec), gastroenteropancreatic neuroendocrine carcinoma (gep-nec), large cell neuroendocrine cancer (lcnec), neuroendocrine carcinomas (nec), neuroendocrine prostate cancer (nepc), small cell lung cancer (sclc)